Category Archives: Business and Investments

Latest From Business and Investments

BIO Investor Forum Company Snapshot: Protagonist Therapeutics

Protagonist

In our final Investor Forum Company Snapshot, we’ve profiled one of the Discovery Companies who will be presenting at the event. Protagonist Therapeutics shares their take on funding challenges and upcoming priorities, plus interesting facts about their company. Don’t miss their presentation first thing Tuesday morning! Company Snapshot What are the short-term and long-term priorities for your company? Protagonist is a peptide therapeutics based technology platform company. Short term priority:  Secure a second collaboration and Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

A What Would George Do? Tribute

For those of you who have been attending BIO events over the past few years, you’ve not only come to know the One-on-One Partnering System, but BIO staff as well.  In particular, our Partnering Guru George MacDougall, – the very person our blog is named after!  Recently, George accepted a position at another DC non-profit and is moving on from BIO.  In honor of all his hard work, exceptional customer service, and contributions to the Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum Company Snapshot: Immune Design

immunedesign

In the third installment of the Investor Forum Company Snapshots, hear from Immune Design Corp. The CEO of the company, Dr. Carlos Paya, will be presenting next week at the 10th Annual BIO Investor Forum on Tuesday afternoon. Company Snapshot What are the short-term and long-term priorities for your company? Short term: focus on validating in patients a product from each of our two novel technologies.  We will be conducting testing of : 1) An Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Medical Innovation at Risk

Scientists

The National Venture Capital Association’s MedIC Coalition recently released a report showing U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investments towards Europe and Asia. The report, Vital Signs: The Threat to Investment in U.S. Medical Innovation and the Imperative of FDA Reform, strongly indicates that America’s medical innovation economy is in grave danger of losing its primary source of funding, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Perspective on Market Valuation for Biotech Drug Developers

Graph

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% are working on molecular tools, diagnostics, biofuels, and other biotech endeavors. One question that is often asked with respect to drug-focused biotechs is: How big are they compared to traditional pharmaceutical companies? How many are valued as small start-ups vs large, or mid-size pharmas? It turns out that more than half the sector trades with a market valuation of less Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,